Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Dechra Pharmaceuticals PLC Director's Dealing 2017

Apr 24, 2017

4797_dirs_2017-04-24_25937642-c07f-44e6-95c5-0f35283caab0.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1418D

Dechra Pharmaceuticals PLC

24 April 2017

24 April 2017

Dechra® Pharmaceuticals PLC

(Dechra or the Company) 

In accordance with article 19(1) of the Market Abuse Regulations, the Company was notified today that due to a change in personal circumstances Ian Page's total beneficial interest in the Company is now 811,308 shares, which represents 0.871% of the current issued share capital.

The reduction in his beneficial shareholding relates to shares held by his sons, Andrew, David and Michael Page, who are no longer classified as a connected person under the Market Abuse Regulations.

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Form

1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a) Name Ian Page
2. Reason for the notification
a) Position/status Director
b) Initial notification/

amendment
Initial Notification
3. Details of the Issuer
a) Name Dechra Pharmaceuticals PLC
b) LEI code N/A
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument

Identification code
Ordinary Shares of 1 pence each

ISIN: GB0009633180
b) Nature of the transaction Shares held by sons, who are no longer connected people
c) Price(s) and volumes(s) Price(s)

Nil cost

Nil cost

Nil cost
Volume(s)

2,600

2,000

2,000
d) Aggregated information

-   Aggregate volume

-   Price
6,600

Nil cost
e) Date of the transaction 2017.04.24
f) Place of the transaction Outside a trading venue

For further information, please contact:

Suzana Cross, Company Secretary           

Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHOKQDBDBKDCQB